Regulatory status CJC-1295 is not FDA-approved for any indication
Semaglutide (Wegovy) achieves this in approximately 30% of patients
We also know that, despite their proven effectiveness overall, some people are non-responders to one or more GLP-1s
Oscillospira has been of high interest in microbiome research, as they account for a high proportion of the fecal microbiome and have been implicated in the pathogenesis of a multitude of metabolic and inflammatory diseases [56, 57]
Currently, nearly 100 million people globally are affected by DR, and as the prevalence of diabetes continues to rise, this number is expected to grow, posing a significant burden on public health (82)
Below, you'll see a comparison table of Brello Health vs popular GLP-1 providers :